My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Apixaban Generic

Apixaban Generic


apixaban genericis an expensive drug used to lower the chance of stroke in people with a medical condition called atrial fibrillation. It is also used to treat or prevent clots in the lungs or in the veins. This drug is slightly less popular than comparable drugs. There are currently no generic alternatives for Eliquis. It is covered by most Medicare and insurance plans, but some pharmacy coupons or cash prices may be lower. The lowest GoodRx price for the most common version of Eliquis is around $424.65, 19% off the average retail price of $526.54. Compare anticoagulants.

Drug Interactions

  • 190 major drug interactions (720 brand and generic names)
  • 202 moderate drug interactions (815 brand and generic names)
  • 8 minor drug interactions (10 brand and generic names)

How popular is Eliquis?

apixaban genericis the second most popular anticoagulant, a class of medications that also includes Coumadin (jantoven, warfarin), Xarelto, and Pradaxa. Commonly referred to as blood thinners, drugs in this class help to prevent blood clots that can cause deep vein thrombosis, pulmonary embolism, angina, stroke and heart attack.

When will generic apixaban generic be available?

There are two things keeping generic Eliquis off the market for now. First, the FDA has granted Eliquis market exclusivity, which expires on December 24, 2017 (Market exclusivity prevents competitors from submitting new drug applications). There is also a patent on Eliquis which expires in February 2023. The patent prevents competitors from manufacturing and distributing alternatives.

Side Effects

  • Blood in the eyes
  • blood in the urine
  • bloody or black, tarry stools
  • bruising or purple areas on the skin
  • confusion
  • constipation
  • coughing up blood
  • decreased alertness
  • difficulty swallowing
  • dizziness
  • fainting
  • fast heartbeat
  • headache
  • hives, itching, skin rash
  • joint pain or swelling
  • nausea and vomiting
  • nosebleeds


Premature discontinuation increases risk of thrombotic events; if discontinued for reason other than bleeding or therapy completion, consider alternative anticoagulant. Risk of spinal/epidural hematoma in anticoagulated patients receiving neuraxial anesthesia or undergoing spinal/epidural puncture (see full labeling); monitor for signs/symptoms of neurological impairment. Increased risk of bleeding; evaluate any signs/symptoms of blood loss; discontinue if active pathological hemorrhage occurs. Patients with prosthetic heart valves, as initial treatment of PE in hemodynamically unstable patients or who require thrombolysis or pulmonary embolectomy: not recommended. Moderate hepatic impairment. Severe hepatic impairment: not recommended. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: not recommended.

Which patents cover Eliquis, and when can generic versions of Eliquis launch?

Eliquis is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ELIQUIS is apixaban generic. There are twenty-eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the apixaban profile page.


Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

use of indwelling epidural catheters

concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants

a history of traumatic or repeated epidural or spinal punctures

a history of spinal deformity or spinal surgery

Know More About This Medicine and Buy Now :